Efficacy and Safety of Selpercatinib in Chinese Patients With RET Fusion-Positive Non-Small Cell Lung Cancer: A Phase 2 Trial

被引：0

作者：

Lu, S. ^{[1
]}

Cheng, Y. ^{[2
]}

Huang, D. ^{[3
]}

Sun, Y. ^{[4
]}

Wu, L. ^{[5
]}

Zhou, C. ^{[6
]}

Zhou, J. ^{[7
]}

Guo, Y. ^{[8
]}

Chen, L. ^{[9
]}

Shao, J. ^{[9
]}

机构：

[1] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Caner Ctr, Shanghai, Peoples R China

[2] Jilin Canc Hosp, Dept Thorac Oncol, Changchun, Peoples R China

[3] Tianjin Med Univ Canc Inst & Hosp, Dept Thorac Oncol, Tianjin, Peoples R China

[4] Shandong Univ, Jinan Cent Hosp, Dept Oncol, Jinan, Peoples R China

[5] Hunan Canc Hosp, Dept Thorac Med 2, Changsha, Peoples R China

[6] Guangzhou Med Univ, State Key Lab Resp Dis, Natl Clin Res Ctr Resp Dis,Resp Med Dept, ffiliated Hosp 1,Guangzhou Inst Resp Hlth, Guangzhou, Peoples R China

[7] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Resp Dis, Hangzhou, Peoples R China

[8] Tongji Univ, Sch Med, Shanghai East Hosp, Dept Med Oncol, Shanghai, Peoples R China

[9] Eli Lilly & Co, Oncol, Shanghai, Peoples R China

来源：

JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 10期

关键词：

Selpercatinib; RET fusion-positive NSCLC; China; ORR;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MA02.01

引用

页码：S888 / S889

页数：2

共 50 条

[1] Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer
Drilon, A.
Oxnard, G. R.
Tan, D. S. W.
Loong, H. H. F.
Johnson, M.
Gainor, J.
McCoach, C. E.
Gautschi, O.
Besse, B.
Cho, B. C.
Peled, N.
Weiss, J.
Kim, Y. -J.
Ohe, Y.
Nishio, M.
Park, K.
Patel, J.
Seto, T.
Sakamoto, T.
Rosen, E.
Shah, M. H.
Barlesi, F.
Cassier, P. A.
Bazhenova, L.
De Braud, F.
Garralda, E.
Velcheti, V.
Satouchi, M.
Ohashi, K.
Pennell, N. A.
Reckamp, K. L.
Dy, G. K.
Wolf, J.
Solomon, B.
Falchook, G.
Ebata, K.
Nguyen, M.
Nair, B.
Zhu, E. Y.
Yang, L.
Huang, X.
Olek, E.
Rothenberg, S. M.
Goto, K.
Subbiah, V.
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (09): : 813 - 824
[2] Efficacy and safety of selpercatinib in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer: a phase II clinical trial (LIBRETTO-321)
Lu, Shun
Cheng, Ying
Huang, Dingzhi
Sun, Yuping
Wu, Lin
Zhou, Chengzhi
Guo, Ye
Shao, Jingxin
Zhang, Wanli
Zhou, Jianying
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
[3] Efficacy and safety of pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancer
Zhou, Qing
Zhao, Jun
Chang, Jianhua
Wang, Huijie
Fan, Yun
Wang, Ke
Wu, Gang
Nian, Weiqi
Sun, Yuping
Sun, Meili
Wang, Xiangcai
Shi, Huaqiu
Zheng, Xiangqian
Yao, Sheng
Qin, Mengmeng
Shen, Zhenwei
Yang, Jason
Wu, Yi-Long
CANCER, 2023, 129 (20) : 3239 - 3251
[4] Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer patients: a systematic review
Yunita, E.
Santoso, V. Febrian
Santoso, A. Febrian
Kurniawan, A.
ANNALS OF ONCOLOGY, 2024, 35 : S1377 - S1378
[5] Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial
Subbiah, Vivek
Gainor, Justin F.
Oxnard, Geoffrey R.
Tan, Daniel S. W.
Owen, Dwight H.
Cho, Byoung Chul
Loong, Herbert H.
McCoach, Caroline E.
Weiss, Jared
Kim, Yu Jung
Bazhenova, Lyudmila
Park, Keunchil
Daga, Haruko
Besse, Benjamin
Gautschi, Oliver
Rolfo, Christian
Zhu, Edward Y.
Kherani, Jennifer F.
Huang, Xin
Kang, Suhyun
Drilon, Alexander
CLINICAL CANCER RESEARCH, 2021, 27 (15) : 4160 - 4167
[6] SORAFENIB IN PATIENTS WITH RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER
Horiike, Atsushi
Takeuchi, Kengo
Uenami, Takeshi
Kawano, Yuko
Tanimoto, Azusa
Kaburaki, Kyohei
Kobayashi, Hiroshi
Gyotoku, Hiroshi
Nishizawa, Hironari
Tambo, Yuichi
Nakatomi, Katsumi
Yanagitani, Noriko
Ohyanagi, Fumiyoshi
Hagiwara, Sachiko
Motoi, Noriko
Ishikawa, Yuichi
Horai, Takeshi
Nishio, Makoto
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S898 - S898
[7] Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial
Drilon, Alexander
Subbiah, Vivek
Gautschi, Oliver
Tomasini, Pascale
de Braud, Filippo
Solomon, Benjamin J.
Tan, Daniel Shao-Weng
Alonso, Guzman
Wolf, Juergen
Park, Keunchil
Goto, Koichi
Soldatenkova, Victoria
Szymczak, Sylwia
Barker, Scott S.
Puri, Tarun
Bence Lin, Aimee
Loong, Herbert
Besse, Benjamin
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (02) : 385 - +
[8] The efficacy and safety of selective RET inhibitors in RET fusion-positive non-small cell lung cancer: a meta-analysis
Ke, Jun-yi
Huang, Shu
Jing, Zhi-tao
Duan, Min-chao
INVESTIGATIONAL NEW DRUGS, 2023, 41 (05) : 768 - 776
[9] Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancer
Horiike, Atsushi
Takeuchi, Kengo
Uenami, Takeshi
Kawano, Yuko
Tanimoto, Azusa
Kaburaki, Kyohei
Tambo, Yuichi
Kudo, Keita
Yanagitani, Noriko
Ohyanagi, Fumiyoshi
Motoi, Noriko
Ishikawa, Yuichi
Horai, Takeshi
Nishio, Makoto
LUNG CANCER, 2016, 93 : 43 - 46
[10] Safety and efficacy of pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancer: Update from the ARROW trial.
Curigliano, Giuseppe
Gainor, Justin F.
Griesinger, Frank
Thomas, Michael
Subbiah, Vivek
Baik, Christina S.
Tan, Daniel Shao-Weng
Lee, Dae Ho
Misch, Daniel
Garralda, Elena
Kim, Dong-Wan
Paz-Ares, Luis G.
Mazieres, Julien
Liu, Stephen V.
Kalemkerian, Gregory Peter
Houvras, Yariv
Bowles, Daniel W.
Mansfield, Aaron Scott
Zalutskaya, Alena
van der Wekken, Anthonie J.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 3 4 5 →